focus -WSS

focus

author：fashion 2025-10-01 10:59:59 - browse：285

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Marc Tessier

explore

focus

WSS

Biden to sign 'historic' executive order on how US military handles sexual assault cases

GOP inquiry over gain

Tuskegee Airman Raymond Cassagnol dies at 102

Supreme Court rules employers must be more accommodating of religious observance

'The boss' wants server deleted: New allegations emerge in Trump indictment

Eating disorder hotline's move to chatbot carried cost for volunteers

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Brazil's Jair Bolsonaro is barred from running for office until 2030

Walensky prepares to leave CDC — and Congress — behind

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Guidelines to prevent youth baseball injuries need more muscle

GOP inquiry over gain

Medicare details structure of new drug price negotiation program

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Medicare details structure of new drug price negotiation program

Ford recalls 870K F

hotspot

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Thousands protest in Iraq for a second day over burning of Quran in Sweden

'The boss' wants server deleted: New allegations emerge in Trump indictment

As the dark side of IVF slowly comes into focus, even more transparency is needed

VC firm RA Capital starts a new synthetic biology incubator

leisure time

explore

focus

hotspot